← Back to Clinical Trials
Recruiting NCT05200351

NCT05200351 Equine-assisted Therapy for Therapy-resistant Adolescents With Autism Spectrum Disorders, a Replicated AB-design

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05200351
Status Recruiting
Phase
Sponsor Karakter Kinder- en Jeugdpsychiatrie
Condition Emotion Regulation
Study Type INTERVENTIONAL
Enrollment 35 participants
Start Date 2022-02-14
Primary Completion 2024-12

Eligibility & Interventions

Sex All sexes
Min Age 11 Years
Max Age 18 Years
Study Type INTERVENTIONAL
Interventions
Equine assisted Therapy (EAT)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 35 participants in total. It began in 2022-02-14 with a primary completion date of 2024-12.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to assess the (cost)effectivity of Equine assisted Therapy in adolescents with Autism Spectrum disorders.

Eligibility Criteria

Inclusion Criteria: * between 11-18 years old; * a clinical diagnosis of autism spectrum disorders according the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM 5) as diagnosed by a Beroepen in de Individuele Gezondheidszorg (BIG) registered healthcare professional; * insufficient emotion regulation after regular therapy for at least 1,5 years as indicated by a score above clinical cut-off (T-score = 65) on the EDI; * comorbidities are allowed except for those interfering with safety. Exclusion Criteria: * unable to respond to questions (parents or adolescents); * no access to an Internet connection; * insufficient mastery of Dutch language in parents or adolescents; * physically incapable to work with the horses; * unstable medication use; * total intelligence quotient (IQ) equal to or below 80 on the Wechsler Intelligence Scale for Children (WISC-III-R or WISC-V); * allergic or phobic to horses; * insufficient regulation to safely handle the horses; * therapy with horses within the last two years.

Contact & Investigator

Central Contact

Jenny den Boer, Drs

✉ j.denboer@karakter.com

📞 0031-318676611

Principal Investigator

Nanda Lambregt-Rommelse, Prof. Dr.

PRINCIPAL INVESTIGATOR

Radboud/Karakter

Frequently Asked Questions

Who can join the NCT05200351 clinical trial?

This trial is open to participants of all sexes, aged 11 Years or older, up to 18 Years, studying Emotion Regulation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05200351 currently recruiting?

Yes, NCT05200351 is actively recruiting participants. Contact the research team at j.denboer@karakter.com for enrollment information.

Where is the NCT05200351 trial being conducted?

This trial is being conducted at Ede, Netherlands, Heerjansdam, Netherlands, Mill, Netherlands.

Who is sponsoring the NCT05200351 clinical trial?

NCT05200351 is sponsored by Karakter Kinder- en Jeugdpsychiatrie. The principal investigator is Nanda Lambregt-Rommelse, Prof. Dr. at Radboud/Karakter. The trial plans to enroll 35 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology